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Abstract  
 
In this thesis, different methods to improve the microdialysis collection procedure for 
cytokines from brain tissue are presented. The first method was based on stopped flow and 
results indicating that no significant difference in relative recovery between stopped flow and 
continuous flow are shown. The second method is an antibody bead-based enhancement method. 
With the antibody bead-based method, a 3.5 fold increase in the collected concentrations of 
Chemokine (C-C motif) Ligand 2 (CCL2) were observed. However, there was no significant 
increase in the in vivo collection efficiency of Interleukin-6 (IL-6) using the antibody 
enhancement.  Finally the development of an in-house created bead assay is discussed for the 
enhanced collection and quantification for molecules that do not have a commercially available 
bead-based immunoassay kit. The in-house assay when compared to a commercially available kit 
for CCL2 showed that a successful assay can be made using the technique employed. Using this 
method a bead based assay could be made for molecules that do not have these commercially 
available kits.   
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1.0 Introduction 
 
Within the brain, communication between cells occurs via the release of different 
chemicals from presynaptic neurons through the synapse to receptors on the post-synaptic 
neuron. These chemicals are classified in different ways and include low molecular weight 
compounds such as dopamine and serotonin to large molecular weight proteins. Dopamine and 
serotonin represent a class of chemicals referred to as the classical neurotransmitters. 
Neuropeptides such as leucine-enkephalin and neuropeptide Y are considered by some to be 
neurotransmitters and by others to be neuromodulators. A third class of neuromodulators is the 
cytokine proteins.   
 Cytokines are a large class of proteins that are secreted not only by different cells in the 
immune system, but also from different cells within the central nervous system (CNS). 
Cytokines are emitted in response to immunological threat or injury and play an important role in 
development and homeostasis. Additionally, cytokines are known to work within a network of 
different proteins affecting different functions commonly referred to as, the “cytokine network.”   
1.1 History of Neurochemical Collection or Detection in Brain.  
  
The existence of classical neurotransmitters and some neuropeptides was known and 
verified long before there were methods to detect the presence of these chemicals directly within 
the brain extracellular space (ECF) in living beings. By the late 1960s and early 1970s there was 
a tremendous interest in creating chemical analysis tools that would allow for the collection or 
detection of neurotransmitters.   
14 
 
1.1.1 Whole Brain 
 
A common method of obtaining proteins from brain tissue is the use of a biopsy, where a 
small section of tissue is taken out and analyzed. In addition to small sections whole brain biopsy 
is also used where the whole brain is taken out to analyze. This biopsy method is most limited in 
that it only gives a single measurement at the time the sample was taken; changes in protein 
levels that may occur throughout the duration of an injury or disease cannot be analyzed. Not 
being able to analyze protein changes in a temporal manner requires many additional animals. 
1.1.2 In Vivo Electrochemistry 
 
By the mid-1970s, Ralph Adams and colleagues developed the technique of in vivo 
voltammetry to measure the electrochemically active catecholamines.
1
 Around the same time, 
Ungerstedt began to use dialysis tubes with attached inlet and outlet tubing as an “artificial 
capillary” to allow for collection of classical neurotransmitters.2   
Since electrochemical methods are only able to detect chemicals that are redox active, 
this analysis tool is limited in the sampling of neuromodulators since there are many more 
neuromodulators than the biogenic amines that are not redox active including amino acid 
neurotransmitters such as glutamate and GABA.  Cytokines are included in the group that is not 
redox active. For this reason, with respect to in vivo cytokine detection, electrochemistry is not 
an appropriate choice for measurement.   
1.1.3 Push Pull 
 
15 
 
At the same time that electrochemical methods were being developed for catecholamine 
detection, late 1960s, the use of a technique called push-pull perfusion was being developed and 
described for collecting samples from the ECF in awake animals.
3
 In this technique a hollow 
tube with an open end is inserted into the tissue. A perfusion fluid is then pumped into the tube 
and out into the tissue. After a short time, this fluid is then pulled back through the tube using a 
vacuum allowing sample collection. Push-pull has been used to collect peptides within the 
brain.
4, 5
 Push-pull however has limitations as well. There are concerns within the research 
community regarding how much damage is done to the tissue by pushing the fluid into it. 
Kottegoda et al.
6
 show that the use of low flow rates limits the amount of damage done by push-
pull perfusion. However Myers et al.
7
 have compared push-pull to microdialysis and found that 
push-pull caused more tissue damage. Push-pull is also not an analytically clean method of 
collection as microdialysis is thus further sample preparation and separation is often needed 
before detection leading to sample loss and degradation. Only recently has this problem been 
overcome by direct coupling of the separation and detection in-line with the push-pull.
8
   
1.1.4 Microdialysis  
 
Microdialysis is a sampling technique that allows the collection of molecules from the 
tissue of interest. Microdialysis sampling uses an outer semi-permeable membrane that is size 
selective with a defined molecular weight cutoff (MWCO). Solutes that are smaller than the 
membrane MWCO will diffuse through the membrane. Solutes that diffuse across the membrane 
into a perfusion fluid that carries the molecule out of the probe allowing for sample collection 
and analysis. Once collected solutes can then be further analyzed without additional sample 
preparation steps. An in-depth discussion of microdialysis sampling is provided in Section 1.3.  
16 
 
1.2 Cytokine Signaling within the Brain  
 
Cytokines are signaling proteins released by cells of the immune system - macrophages, 
neutrophils, basophils, eosinophils, and lymphocytes.
9
 Cytokines are used as signaling proteins 
to regulate and control the immune response and inflammation.
10
 Cytokines can vary in size and 
structure from 5 to 80 kDa.
11
 Cytokines can only act on those cells that express receptors for 
cytokines. Cytokines have been shown to have autocrine, paracrine and endocrine function 
between immune cells.
12
 
The binding of the cytokine to its receptor will trigger a secondary messenger cascade 
that will regulate transcription factor and vesicle releasing factors. This way cytokines regulate 
the production of further proteins in the immune cells and the release of further cytokines.      
Because the cytokine system is so extensive this section will only go into those specific 
cytokines researched with in this thesis and only their function within the brain. Chemokine(C-C 
motif) Ligand 2(CCL2 or MCP-1) has been shown to alter the permeability of the blood brain 
barrier and regulate vascular control.
13, 14
 
1.2.1 Cellular Origins 
 
Within the brain, cytokines have been found within nearly every type of cell; glial, 
neuron, and astrocytes. Cytokine receptors have also been found in almost every region of the 
brain.
15,16
 The exact reason for the presence of these receptors on neurons is unknown,  but it has 
been proposed that cytokines and chemokines act as a third type of neuronal chemical 
communication  group.
17
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Initial work into identifying cytokines and their receptors within brain tissue has been 
performed mainly with two techniques.  Real time polymerase chain reaction (RT-PCR)
18
 has 
been used to identify cell types within different brain regions that are involved in the cytokine 
network. PCR it is important to point out does not actually detect the protein but the expression 
of the protein, to actually detect cytokines or their receptor proteins requires 
immunohistochemistry approaches.
19
 These techniques identify which cells have cytokines or 
their receptors. However since cytokine function is concentration dependent in many of its roles 
it is important to get a measurement of the actual protein to determine effects on the system.
20, 21
 
Limited time lapse studies done on homogenized tissue has shown that cytokine concentration is  
dynamic in vivo.
9, 11
 These techniques can only offer a single time point examination of the 
concentration. The same problem occurs with a biopsy of the tissue. Studies have been done 
were tissue has been taken from different subjects at different time points but to account for the 
variation between individuals the population size must be increased. To truly gain an 
understanding of the change in the concentration of the cytokines over time, a continuous 
sampling technique is needed.  
1.2.3 Role in Disease 
 
Traumatic brain injury is a major health concern even with advancements of modern 
medicine.
22
 It is known that the wound healing response within the brain can cause additional 
damage to tissue around the initial wound. There are currently limited treatments to reduce this 
additional damage. Since the cytokine network is responsible for the regulation of the wound 
healing response, investigation into this network within the brain could lead to treatments that 
would prevent this secondary damage and lead to better outcomes. Cytokines have also been 
18 
 
described in multiple disease states with in the brain.
23-25
 While cytokines have been identified 
with these disease states, their affects and effects on the states are widely not known. The 
difficulty of understanding their role in the wound response and these diseases is that real time 
measurements are needed since many cytokines function through a concentration gradient to see 
if there is a change in this concentration.  Real time sampling would allow for experiments to 
help determine factors that may change these concentrations. In addition there is not a non-
invasive way to monitor concentration changes of cytokines with in the brain. Thus a base 
expectation of cytokine profiles and the expected concentrations caused the sampling procedure 
must be established before treatments can be compared.  
1.3 Microdialysis 
 
As stated earlier microdialysis is a sampling technique. This technique is minimally 
invasive and allows for sampling across time points within the same tissue. The method of 
microdialysis collection is a perfusate fluid is pumped through a canula. The end of this canula is 
surrounded by a semi-permeable membrane. Different semi-permeable membranes with different 
materials chemistry and molecular weight cutoff are available to use for different experiments.  
A perfusion fluid flows through the membrane inner lumen to be collected.   This method of 
collection is graphically depicted in Figure 1.1. 
19 
 
 
 
Figure 1.1: Graphical Representation of Microdialysis.
26
  
 
Microdialysis depends on solute passive diffusion for the collection. The factors that control this 
overall mass transport process include the relation of mass transport resistances of the system. 
These resistances are described as Resistance to dialysate (Rd), Resistance to Membrane (Rm), 
Resistance to Tissue (Rts) or in the case of in vitro, Resistance to Sample Media (Rsm). These 
resistance values define how easily the analyte moves by diffusion through the areas that they 
represent. The relation to these resistances and their effect on the Relative Recovery (RR) is 
shown in Equation 2.    
                                 ( )  
              
               
                             (1) 
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Resistance terms are defined in equation 3, 4, and 5. With all terms and symbols defined 
in the List of Abbreviations and Symbols. In these equations,  ri is the inner membrane radius, rα 
is the probe inner cannula radius, ro is the outer membrane radius, L is the effective membrane 
length, Dd is the analyte dialysate diffusion coefficient, Dm is the analyte diffusion coefficient 
through the membrane, Dq is the analyte diffusion coefficient in the quiescent medium external 
to the probe, Φm is the volume fraction of the membrane accessible to water, and Φq is the 
volume fraction in the quiescent sample medium.  
           
(
  
  (         )
)
                           (2) 
   
  (     )
        
     (3) 
   
  (     )
       
    (4) 
                                                         
 
      √    
                                    (5) 
Relative Recovery should not be confused with Absolute Recovery. Absolute Recovery 
expresses the amount of mass that is collected, because of this it can never go above 100% and 
can never be negative. Relative Recovery is a comparison of concentrations. The amount of 
analyte collected is often expressed as relative recovery (RR) or extraction efficiency (EE). 
Another benefit to microdialysis is that it allows for the real time analysis of these 
concentrations. Since the sampling technique is continuous, changes in concentration can be 
monitored over time. The limitation to this real time analysis is the volume of sample needed for 
quantification and flow rate used in collection. The sample volume needed is dependent on the 
detection method used, with a range of 25 µL to 100 µL or more. This means that for lower 
21 
 
volumetric perfusion rates (0.2 -0.5 µL/min) time resolution is limited. Higher volumetric 
perfusion rates (1-5µL/min) are needed to have better time resolution. The relationship between 
flow rate and Relative Recovery with known and estimated values for has been described and is 
shown in Figure 1.2.  
 
 
Figure 1.2: Relationship between Flow Rate and Extraction Efficiency  
A slower flow allows for a higher relative recovery but also increases the time need to 
collect the sample. Thus a tradeoff is often needed with respect to time resolution and the amount 
recovered. Time resolution is the amount of samples that can be taken per increment of time thus 
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the more samples that can be taken in smaller amounts of time the better the time resolution. It is 
important to understand when doing microdialysis experiments what time resolution is required 
and the optimal flow rate that will gather at least the minimal amount of sample volume need in 
that time frame.  
1.4 Protein Collection  
 
Microdialysis collection has had some problems with the collection of larger molecules 
such as proteins.  Membranes have been designed with 3000 kDa molecular weight cutoff 
(MWCO) however for some proteins their recovery still remains low.
26
 This poses a particular 
problem with cytokines as the relative recovery of some cytokines has been reported to be low 
(10-15%). Waelgaard et al. found that the relative recovery of cytokines varies greatly and 
appears to be dependent on other factors besides size.
27
 The exact reasons for these low recovery 
values are not known at this time, however it is believed that hydrophobic interactions with the 
membrane is one of the causes. The combination of the low recovery rate and low concentration 
in vivo systems pushes the limits of current detection methods. In this work we attempt to 
improve the relative recovery to allow better quantification of cytokines. 
23 
 
 
Figure 1.3: Graphical representation of Microdialysis and Antibody-Enhanced Microdialysis.  
In this work we use  the addition of an affinity agent to the perfusion fluid to increase the 
net flux across the membrane. This is graphically represented in Figure 1.3.  The mechanism of 
this increase in net flux comes from the reduction of the free analyte in the perfusion fluid by 
binding to the affinity agent. The reduction in free analyte in the perfusion fluid drives more 
targeted solute to diffuse across the membrane thus increasing the net flux. Work has been done 
to identify appropriate affinity agents for cytokines, antibodies and heparin,
28
 and human 
albumin serum.
29
 In these experiments we use antibodies as the affinity agents Antibodies have a 
high specificity for their target as well as a high binding affinity. In this work we will use free 
antibodies instead of antibodies attached to bead because it has been shown that there is a loss of 
bead do to aggregation and settling.
28
 These values are different for each antibody and antigen 
but the range of these binding affinities are reported to have K(association) values of approximately 
24 
 
10
8
. This insures that almost the entire antigen is bound to the antibody if sufficient 
concentrations of antibody are present. This works well for the affinity agent microdialysis to 
ensure an increase in flux since there is very little free antigen present in the dialysate. In 
addition to antibodies, heparin has been used as an affinity agent. While heparin has a lower 
binding affinity to cytokines than antibodies it has the advantage that after collection the 
cytokines could be dissociated from it. This could allow for preconcentration of the cytokines 
before detection.          
1.5 Enzyme-linked Immunosorbent Assay 
 
One method that is able to quantify within the range of the collected cytokines is 
Enzyme-linked Immunosorbent Assay (ELISA). ELISA is a specific type of sandwich 
immunoassay. In a standard sandwich immunoassay a capture antibody is fixed onto a surface, 
sample is then added and the antigen is allowed to bind to the capture antibody, a second 
antibody is then added with a marker that is then detected. An ELISA instead of having a marker 
attached to the second antibody, also known as the detection antibody, an enzyme is attached. 
Most commonly this enzyme has products that are able to be detected by UV/Vis absorption. 
Thus once the detection antibody has bound the antigen substrate to the enzyme is added and 
converted into a product that is then detected. This method allows for amplification of the signal 
over a standard immunoassay. A graphical representation of the ELISA procedure is depicted in 
Figure 1.4. ELISA is commonly used to measure cytokines in serum and homogenized tissue 
30,31
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Figure 1.4: Pictorial representation of the ELISA procedure.
32
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1.6 Bead Based and Microarray Immunoassays 
 
To reduce the sample volume needed to measure cytokines, development of microarrays 
and bead based assays have been created. Current commercially available bead based assays 
require sample volumes as low as 25µL, while developing microarrays can use as little as 
20µL.
33-35
 Bead based assays are able to reduce the volume needed by increasing the surface area 
of the assay. In a standard immunoassay the capture antibody is fixed to a flat surface. In a bead 
based assay the capture antibody is fixed to functionalized beads. The use of these beads 
increases the amount of surface area and thus the amount of capture antibody. These beads are 
also suspended in the sample solution thus a smaller overall volume of sample is needed to have 
the same amount of exposure to capture antibody.  Figure 1.5 is a graphical representation of the 
components of a bead based assay.  
 
27 
 
Figure 1.5: Pictorial representation of the bead-based assay.
36
 
 A second advantage to the bead based and microarray assays are that they may be 
multiplexed.  With the same 25µL sample a bead based assay could detect up to 100 different 
analytes.
34
 Developing microarrays also are able to increase the number of analytes detected in a 
single sample, though the number of analytes solely depends on the fabrication method.  One 
problem with this high level of multiplexing is cross reactivity. Each analyte that you add to the 
array or bead set must be checked for cross reactivity with the others. This extensive pretesting 
with this level of multiplexing is time consuming. The benefits of lower sample size needed and 
multiplexing makes bead based and microarray immunoassays appropriate for detection of 
several cytokines at once that have been collected by microdialysis. This multiplexing is 
important since cytokine responses are often described as a network of chemical messengers 
allowing the researcher to investigate the whole network rather than one cytokine at a time.  
1.7 Significance and Goal of Thesis 
  
The work presented here attempts to develop microdialysis methods that will increase 
relative recovery of cytokines which would allow for quantification in later treatment 
experiments. This work will focus on the use of microdiaylsis as a method to collect cytokines 
from extracellular fluid in brain tissue. Microdialysis will be used in conjunction with 
appropriate detection methods, which in this research will focus on ELISA and bead based 
immunoassay. This collection and quantification will establish extracellular concentrations of 
cytokines and the changes there in over time. The first part of this work will focus on the 
increase of relative recovery of cytokines which are in naturally low concentrations in the 
extracellular fluid. Previous studies of cytokine collections by microdialysis have shown that 
28 
 
they have a low(5% - 20%) relative recovery.
28
 This presents a difficulty in quantification of 
cytokines when microdialysis is used as the sampling method. Cytokines are present in low (pM) 
range in vivo. A low relative recovery means that the concentration of the cytokine in the sample 
may be below the limits of detection for current quantification methods. The second part of this 
work will be to test the developed methods in vivo to ensure that cytokine relative recovery is 
increased in vivo for use with later treatment experiments.  
In Chapter 2 the use of a microdialysis technique of stopped-flow will be discussed for 
the increase of relative recovery of the cytokines CCL2 and Interferon Gamma (IFN-γ). In the 
following chapters (Chapters 3) the use of an affinity agent of antibody specific cytokines CCL2 
and Interleukin-6 (IL-6) to increase relative recovery both in vitro and in vivo (Sprague-Dawley 
rats).  In the following chapter (Chapter 4) the development of a bead based immunoassay for the 
cytokine CCL2 will be discussed and compared to commercially available assays.  
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2.0 Stopped Flow Microdialysis of Chemokine(C-C motif) Ligand 2(CCL2/ MCP-1) and 
Interferon-gamma (IFN-γ) 
 
2.1 Introduction  
 
In this chapter, experiments using stopped flow microdialysis to attempt an improvement 
in the relative recovery of cytokines are described. Stopped flow microdialysis is a method of 
microdialysis sampling in which the perfusion fluid is stopped for a certain amount of time and 
then the flow is resumed. Stopped flow microdialysis is often used in delivery studies, where the 
drug of interest is added to the perfusion fluid and allowed to diffuse into the tissue to either 
suppress or solicit an analyte of interest that is then collected. It is uncertain what factors are 
responsible for the low level of collection of cytokines through microdialysis. In these 
experiments we explore this question and attempt to establish a method that allows for a greater 
collection of cytokines. In these experiments we attempt to give the cytokine the longest 
residence time possible. It is hypothesized that an increase in residence time will increase the 
Relative Recovery. To test this hypothesis the stopped flow method was proposed.  
In these experiments two cytokines, Chemokine (C-C motif) Ligand 2(CCL2/MCP-1) 
and Interferon-gamma (IFN-γ), were examined. IFN-γ was selected because it is present at 
concentrations (5-10 pg/ml)
1
 which are at the lower limits of current detection methods as 
described in chapter 1. CCL2 was selected as a second cytokine because of the wide interest for 
measuring this cytokine in neurological disorders. An improvement in recovery would lead to a 
higher concentration in the sample. A higher concentration within the sample would prevent 
some samples being below the limits of detection of the ELISA. This would allow for a greater 
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sampling concentration range with-in the tissue for areas of interest that may have lower in vivo 
concentrations. 
2.2 Experimental Section 
 
2.2.1 Materials  
 
Rat MCP-1 and rat IFN-γ was purchased from Prepro-Tech INC (Rocky Hill, NJ). 
Microdialysis probes CMA/20 14/10 polyethersulfone membrane (PES) and 10-mm length and 
CMA 402 Syringe Pump were purchased from CMA/Microdialysis (Stockholm, Sweden). Fetal 
bovine serum (FBS) was purchased from Sigma (St. Louis, MO). Rat MCP-1 BD optEIA ELISA 
kit and rat BD optEIA IFN-γ kit were purchased from BD Biosciences (San Jose, CA). 
Absorbance was measured with Infinite M200 plate reader purchased from Tecan (Research 
Triangle Park, NC). 
2.2.2 Methods 
 
2.2.2.1 Stopped Flow 
 
Sample solutions with concentrations of 2000 pg/mL of CCL2 or IFN-γ in phosphate 
buffered saline (PBS) with 10% fetal bovine serum (FBS) by volume at pH 7 were generated.  
Cytokine samples were then placed on a heated stir plate (35 ºC) and mixed during microdialysis  
sampling. A perfusion fluid of PBS with 10% FBS was then made. Microdialysis probes were 
inserted into the sample and a flush was performed at 5µL/min until all air was removed from the 
tubing. Two stopped flow times were used in separate experiments: one for 30 minutes and the 
35 
 
second for 60 minutes. Following the stopped flow, two collection flow rates were tested: one of 
5µL/min and one of 2 µL/min. Samples were collected for 15 minutes, which delivered a sample 
volume of 75 µL and 30 µL, respectively. For the 2 µL/min the process was then repeated to give 
a final sample volume of 60 µL. Samples were frozen and stored at -20°C for no longer than 48 
hours prior to analysis.   
Once thawed, 50 µL was taken from each and mixed with 50 µL of the ELISA assay 
diluent, which brought the final sample volume to 100 µL as per kit specifications. These 
samples were then analyzed according to kit protocols and the absorbance was measured by an 
Infinite M200 plate reader. Quantification was performed by a comparison to standards on the 
same plate. 
2.2.2.2 Continuous flow 
 
Sample solutions with concentrations of 2000 pg/mL of CCL2 or IFN-γ in PBS with 10% 
FBS at pH 7 were used. These solutions were then placed on a heated stir plate (35 ºC) and 
mixed while sampling. A perfusion fluid of PBS with 10% FBS was then made. Microdialysis 
probes were inserted into the sample and a flush was performed at 5µL/min until all air was 
removed from the tubing. Flow rates of 0.5, 1, and 2µL/min were then used to sample for 60 
minutes, giving sample sizes of 30, 60 and 120 µL, respectively. Samples were then frozen and 
stored for no longer than48 hours at -20°C. Once thawed, sample volumes of 30, 50, and 100 µL 
were taken and mixed with 70, 50, and 0 µL assay diluent, respectively, to bring the final sample 
volume to 100 µL. The samples were then run according to kit protocols and the absorbance was 
measured by an Infinite M200 plate reader. Quantification was performed by a comparison to a 
standard curve run on the same plate. 
36 
 
2.2.2.3 Methyl Orange  
 
A solution of 10 µM Methyl Orange in 10mM phosphate buffer was generated. It was 
heated to 35°C and stirred during collection. A perfusion fluid of 10mM phosphate buffer was 
flushed and allowed to sit for 30 minutes or 1 hour in two trials. A collection flow rate of 2 
µL/min was used to collect for 15 minutes to give a volume of 30 µL, this was repeated after a 
second stopped flow to allow for a final sample volume of 60 µL. Three samples of 60 µL for 
each stopped time were then compared to a continuous flow of 2 µL/min. This was done to 
duplicate the methods used in the cytokine collection. Absorbance was then measured using 
Infinite M200 plate reader. 
 
2.2.3 Work-Flow Diagram  
 
Figure 2.1 Work Flow diagram of Stopped-Flow Experiments. 
2.2.2.3 Statistics  
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Stopped Flow data were compared to each other with respect to stopped flow times and 
recovery flow rates using ANOVA (Microsoft Excel). Stopped Flow data were compared to 
Continuous Flow data using ANOVA(Microsoft Excel).   
2.3 Results 
 
2.3.1 Stopped Flow Collections of CCL2 
 
It was found that the stopped flow microdialysis gave a very large range of recovery 
values. In some cases the collection value would be greatly improved, while in others the amount 
recovered was below the detection limits. Figure 2.2 shows the average of six collections with 
error bars representing one standard deviation.  
The 5 µL/min collection flow rate gave average relative recoveries of 14.79%±14.19% 
and 12.40%±11.83% at 60 minutes and 30 minutes stopped flow times, respectively. The 2 
µL/min flow rate collection gave average relative recoveries of 17.27%±16.80% and 
14.51%±14.06% at the 60 minute and 30 minute stopped flow times, respectively. No significant 
difference was seen with the stopped flow in respect to stopped flow time or collection flow rates 
(p=0.21, p=0.19 respectively). 
2.3.2 Continuous Flow Collections of CCL2 
Continuous flow gave average values where n=6 of 5.58% ± 2.71%, 3.39% ± 1.32%, and 
1.92% ± 0.97% at flow rates of 0.05 µL/min, 1 µL/min, and 2 µL/min, respectively. This is 
shown graphically in Figure 2.3. No significant difference was seen in the flow rates (p=0 .13).  
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2.3.3 Stopped flow Collections of IFN-γ 
 
The stopped flow of the IFN-γ also evidenced large variation. Recorded relative 
recoveries of 8.95%±8.01% and 7.27%±.14% (n=6)  were observed at a collection flow rate of 5 
µl/min for 30 minutes and 60 minutes stopped flow, respectively. Relative recoveries of 
5.93%±3.07% and 3.95%±3.82% were observed at collection flow rate of 2µL/min at 30 minutes 
and 60 minutes stopped flow, respectively. This is shown graphically in Figure 2.4. No 
significant difference was seen in the stopped flow in respect to stopped flow time or collection 
flow rates( p =0.17 , p = 0.15 respectively). 
2.3.4 Continuous flow Collection of IFN-γ 
 
Continuous flow collection of IFN-γ gave average relative recoveries of 5.57% ± 2.16%, 
2.33% ± 1.48%, and 0.81% ± 0.20% at flow rates of 0.5, 1, and 2 µL/min. This is shown 
graphically in figure 2.5. No significant difference was seen in the flow rates (p =0.11). 
2.4 Methyl Orange Stopped Flow and Continuous Flow Collection 
  
Continuous flow collection of Methyl Orange gave an average relative recover of 
34.23%±2.1%. Stopped flow with a stopped time of 30 minutes gave an average relative 
recovery of 47.21%±3.41%. Stopped flow with a stopped time of one hour gave an average 
relative recovery of 49.14%±2.67%. Significant difference was seen between both stopped flow 
times in comparison to the continuous flow and no significant difference between the two 
stopped flow times (p = 0.003, p = 0.34 respectively) 
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Figure 2.2 Results of Stopped Flow Collection of CCL2. 
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Figure 2.3 Results of Continuous Flow of CCL2.  
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Figure 2.4 Results of Stopped Flow Collection of IFN- γ. 
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Figure 2.5 Results of Continuous Flow of IFN-γ 
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Figure 2.6: Results of Methyl Orange Stopped Flow 
2.4 Discussion  
 
In these experiments, the use of stopped flow microdialysis to increase the relative 
recovery of two cytokines, CCL2 and IFN-γ, was investigated. In both studies the stopped flow 
had an average relative recovery higher than that of the continuous flow, an increase in 
percentage of 11.69% more recovery in CCL2 and an increase of 3.38% in IFN- γ with respect to 
their highest percentages from stopped flow to continuous. However, the variation was so great 
that this could not be stated as a significant increase, or that it was a reliable increase for each 
sampling. There are several factors that could be causing the large variation in the stopped flow 
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microdialysis, including but not limited to run to run error, non-specific absorption, analyte loss 
due to degradation, and immunoassay error. 
The relative recovery values 5.6% and 5.5% for CCL2 and INF-γ of the continuous flow 
experiments are similar to those previously reported of 8.6% and 1.3% respectively.
1
 This 
supports the hypothesis that there may be an effect in the stopped flow sampling that is having an 
increase effect on the variation. Since the samples were both frozen no longer than 48 hours and 
quantified by the same technique,  it is possible that the extended time in the stopped flow 
experiments allowed the cytokines to bind to places of lower affinity. In the continuous flow 
experiments, the cytokines would not have enough time to non-specifically bind to areas of 
lower affinity. If this is the case, then the non-specific binding amounts would be hard to predict.  
In addition, with longer sampling time, a saturation effect should be seen. Also, an experiment in 
which a high concentration of cytokine is infused through the probe before sampling to saturate 
the non- specific sites may decrease this variation. If the variation caused by the non-specific 
binding is lowered, the stopped flow method may pose as a valid way of increasing the relative 
recovery of these cytokines.  
This reduction in variation may also allow for the comparison of the 5 µL/min to 2 
µL/min collection flow rates.  With the current data, there is no significant difference between 
the two collection flow rates. This is contradictory to established microdialysis theory, since the 
2 µL/min should have higher relative recovery than the 5 µL/min. With a reduction in the 
variation, a difference may be seen and a comparison could be performed. In addition, a 
comparison of the 30 minute versus the 60 minute stopped flow times could be done. It may be 
worthwhile to see if the longer time had any impact on the effectiveness of the collection.  
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In an attempt to further understand this variation an experiment using methyl orange 
instead of the cytokines was performed. Following the same methods used with the cytokine the 
variation was able to be reduced to see significant difference between the stopped flow and the 
continuous flow. Given these results it is currently believed that the variation with the cytokine 
experiments was most likely caused by the size of the molecule and its tortuous path through the 
probe under equilibrium  
2.5 References 
 
1. Duo, J. Affinity Microdialysis Sampling of Cytokines. Rensselaer Polytechnic Institute, 
Troy, New York, 2009.  
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3.0 In Vivo Collection and Quantification 
 
3.1 Introduction 
 
A variety of different experimental approaches have been applied to elucidate the 
presence of cytokines in the central nervous system.  These methods include:  1) mRNA analysis 
via in situ hybridization or Northern blot analysis;
1
 2) radioimmunoassay or ELISA for protein 
content; 3) radiolabeled cytokine studies in brain slices using autoradiography to map out 
receptor sites; 4) immunohistochemistry; 5) different imaging methods to map receptors;
2
 and 6) 
different cell lines exposed to different permutations of cytokines to release neuropeptides or 
exposure of neuropeptides to release cytokines. While all these measurement methods serve their 
purpose to map out the different cytokine locations, none of these methods allows for real-time 
in vivo cytokine collection, which is of great interest to numerous neuroscience researchers.   
 The difficulty with all of these different techniques is that either they do not provide 
actual protein concentrations especially from the extracellular space or the animal has to be 
sacrificed to obtain protein content. For example, mRNA expression does not always equate to 
actual protein concentrations.
3, 4
 Immunohistochemical analyses do not allow for measurements 
of concentrations over time within the same animal. For these reasons, there has been interest in 
collecting cytokines from the brain using microdialysis sampling. Microdialysis has been used to 
collect chemokines and cytokines in the brain, but these studies have been predominantly in 
humans since the length of the membranes is typically 10 mm vs. the 1 to 4 mm range used for 
rodents. 
5-7
 
 
Cytokines have been collected from rat brain under traumatic injury conditions.
8
  The 
difficulty with collecting cytokines is their low basal (pg/mL) concentrations combined with low 
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recovery through the microdialysis probe.  Typically collected cytokines with relative recoveries 
(RR= Cdialysate/Csample)  between 5 and 10% for 10 mm 100 kDa MWCO membranes.
9
  For this 
reason, we have been using either free antibodies 
10
 or antibodies immobilized to polymeric 
beads used in the typical Luminex assay for improvement of protein recovery into microdialysis 
sampling probes.
11
     
In this work, affinity microdialysis was used with a polyclonal (detection) antibody 
specific for CCL2.  This antibody was included in the microdialysis sampling perfusion fluid 
allowing the collected dialysate to be quantified using a standard ELISA.   
 
3.2 Methods 
 
3.2.1 In Vitro 
 
Microdialysis probes (CMA 20 PES, 10 mm length, 100 kDa MWCO, CMA 
Microdialysis, Stockholm, Sweden) were immersed into a 5 mL solution of 2 ng/mL CCL2 
(Preprotech, Rocky Hill, NJ) in 10 mM PBS. The solution was heated to 35ºC and stirred. An 
aECFperfusion fluid (153.3mM Na
+
, 4.3mM K
+
, 0.41 mM Mg
2+
, 0.71 mM Ca
2+
, 139.4 mM Cl
-
, 
pH 7.4) with 5% BSA was used as a control. The aECF is an artificial extracellular fluid 
described by McNay and Sherwin.
12
  For antibody-included perfusions the aECF fluid was 
supplemented with the detection antibody from a BD Opt EIA kit (BD Biosciences, San Diego, 
CA) to a dilution of 1:500 from the provided material. The protein concentration for the antibody 
in solution is not provided and is considered proprietary by the manufacturer. Samples were 
obtained every 30 minutes during a 180 min time period. Samples were stored at -20ºC and were 
quantified with BD optEIA MCP-1 Kit the following day.   
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3.2.2 In vivo 
 
3.2.2.1 Surgery 
 
Male Sprague-Dawley rats were purchased from Harlan Laboratories, Inc   
(Madison, WI). Rats were housed in an environmentally-controlled facility with a   
12-hour on/off light cycle and ad libitum access to food and water. Six rats (275-350 g) were 
assigned to either a control or antibody-included perfusion regime. Isoflurane (5%) was 
administered at a flow rate of 0.8 L/min by vaporizer. The rat was secured to the stereotaxic unit 
and anesthesia was maintained by 1-2% isoflurane at 0.5 - 0.8 L/min as needed. Coordinates of 
4.6 mm anterior to bregma, +0.5mm lateral, and +0.5 mm dorsal along the horizontal zero plane 
(ear bars) were used.  After sampling, the probe was removed and the rat was euthanized by CO2. 
All protocols were approved by the University of Arkansas IACUC.  
 
3.2.2.2 Microdialysis 
 
CMA 12 PES (4 mm, 100 kDa MWCO, CMA Microdialysis, Inc., North Chelmsford, 
MA) probes were inserted into the brain.  The aECF perfusion fluid was used in one set of 
animals as a control (n=3). The aECF with antibody (BD Opt EIA detection antibody dilution of 
1:500)  was used in a second set of animals (n=3). After an initial 5 minute flush at 5 µL/min, a 
flow rate of 2 µL/min was used to collect dialysates, and samples were collected every 30 
minutes for 3 hours. Samples were stored on ice, and kept frozen at -20ºC, no longer than three 
days, until quantified using ELISA. We have previously demonstrated that samples remain stable 
for at least one week under these conditions.   
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3.2.2  ELISA 
 
Samples were then quantified with BD optEIA Rat MCP-1 ELISA kit (BD Biosciences, 
San Diego, CA). To meet kit volume specifications, assay diluent (50 µL) from the BD optEIA 
kit was added to dialysate samples (50 µL) to a final sample volume of 100µL. A comparison of 
standards that included the 1:500 dilution of detection antibody to control standards was 
performed. Samples that included the diluted antibody were treated the same way as samples 
without antibody or standards. This included the required step of adding the detection antibody 
to all samples during the sample preparation steps involved with the ELISA. The UV absorbance 
was measured with a Tecan infinite M200 plate reader (Tecan, Research Triangle Park, NC). 
 
3.2.4  Statistics.  
  
Antibody-enhanced values were compared to control values at each time point with a 
paired Students t-test at the 95% confidence level using Microsoft Excel
®
. ANCOVA was 
performed using JMP8
®
 software (SAS Institute, Cary, NC).   
  
3.3 Results 
 
3.3.1  Calibration Curve Statistics  
  
The calibration curves were compared using an Analysis of Covariance (ANCOVA).  
There was no significant difference found between the slopes of the calibration curves 
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(normalized to log-log plots) between samples handled using the standard ELISA protocol and 
antibody-inclusion protocol, p=0.44.  
 
3.3.2  In Vitro Microdialysis  of CCL2 
 
Antibody enhanced microdialysis in vitro showed a significant increase in the relative 
recovery of CCL2 vs. control for both the 1.0 and 2.0 µL/min flow rates figure 3.1.  The 
recovery was 37.5% ±10.2% and 64.8% ±11.7% at flow rates of 2.0 µL/min and 1.0 µL/min, 
respectively. For the controls, the recovery values were 9.6% ±3.4% and 12.2% ±4.1% (n=10), 
respectively, noting there is not a significant difference in the values.  These data are represented 
in Figure 3.1 
 
3.3.3  In Vivo Microdialysis of CCL2 
 
Antibody-included microdialysis samples had CCL2 concentrations of 500±30, 810±100, 
1720±200, 1735±370, 1590±300 pg/ml at time points of 30, 60, 90, 120, and 150 minutes,  
respectively(n=6).  At time point 180, antibody-included sample gave a value over that for the  
highest standard (2000 pg/mL) and thus could not be quantified.  Control samples gave a 
collected value of 560±95, 260±85, 310 ±75, 480±55, 700±200, and 700 ±195pg/mL at time 
points of 30, 60, 90, 120, 150, and 180 minutes respectively(n=6).  A significant difference was 
found between controls and antibody–included at time points of 60, 90, 120, and 150 minutes. 
These data are represented in Figure 3.2 
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3.3.4  In Vitro Microdialysis of IL-6  
 
5 mL of 2ng/mL IL-6 was made up from stock in 10 mM aCEF. It was heated to 35ºC 
and stirred. CMA 20 PES probes were used to sample with a perfusion fluid of aECF. Samples 
were taken every 30 minutes during a three hour time period. Samples were stored at -20ºC and 
were quantified with BD opt EIA the following day. Average relative recoveries of  17.60% 
±3.70% and 56.60%±22.70% were found for the control and antibody infused respectively(n=3). 
These data are represented in Figure 3.3.  
3.3.5 In Vivo Microdialysis of IL-6 
 
For the in vivo collection of  IL-6 using the correct coordinates for the hippocampus, 
values of 279.77± 66.96, 351.79±38.78, 294.44±86.62, 271.44±161.88, 248.14±37.30, 
211.37±30.06 pg/mL were found at time points of 30, 60,90, 120, 150, and 180 minutes 
respectivly for the control(n=3). Values of 257.06±40.41, 286.36±86.77, 364.18±240.04, 
335.33±151.15, 434.46±82.09, 433.14±92.88 pg/mL were found for time points 30, 60, 90, 120, 
150, and 180 minutes respectivly for the antibody-enhanced sample. These data are represented 
in Figure 3.4. 
3.3.6 Comparison of Antibody enhanced Standards to Control   
 
BD optEIA Rat MCP-1 ELISA kit (BD Biosciences, San Diego, CA) Standards were 
prepared in a solution that contained 1:500 dilution of the detection Antibody from the same kit 
in aCEF as well as assay diluent as per kit protocols. Both were then run according to kit 
protocols to see if the additional detection antibody had any effect on the assay. Results are 
graphically represented in Figure 3.5.  
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Figure 3.1: In vitro collection of CCL2.  Error bars represent a standard deviation of n=10 in 2 
µL/min and control, and n=5 in 1µL/min. * Denotes a significant difference to the control at the 
95% confidence level. 
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Figure 3.2:  In vivo collection of CCL2.  Error bars represent a standard deviation were n=6. A * 
denotes significant difference to the control at the 95% confidence level. Antibody-Infused  data 
at time point 180 was over the range of standards so no quantitative value is reported. 
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Figure 3.3  In vitro collection of IL-6.  Values presented are an average were n=3. Error bars 
represent a standard deviation. 
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Figure 3.4  In vivo collection of IL-6.  Values presented are an average of n=3 samples. Error 
bars represent a standard deviation.  
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Figure 3.5 Comparison of Antibody added aCEF and Assay Diluent. Points are an average of 
(n=4). Error bars represent a Standard Deviation.  
3.4 Discussion 
  
In this work, we demonstrate the first usage of antibody-enhanced in vivo microdialysis 
sampling for the chemokine, CCL2 and IL-6.  Pich et al. used antiserum against corticotropin-
releasing factor and observed an approximate two-fold increase in their relative recovery.
13
 This 
increase is most likely caused by the binding to the antibody which serves to increase the flux of 
the targeted analyte into the dialysis probe. For CCL2, we observed an approximate 3.5 fold 
increase in the in vitro relative recovery. This approximate 3.5 fold increase held for the in vivo 
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studies at the time points of 90, 120 and 150. This was somewhat unexpected since differences in 
the mass transfer properties between in vitro and in vivo experiments exist.   
At the 30 minute time point, different scenarios could lead to the observed similar CCL2 
concentrations. The first is that glial cells have been reported to contain MCP-1.
14, 15
 In these 
studies, samples were immediately collected after probe insertion.  This is because the rat was 
under isoflurane anesthesia and after several hours it becomes tricky to maintain rodents under 
this anesthetic. If the probe insertion caused significant release in the CCL2 from disrupted glial 
cells, it is likely the concentrations will be much higher in the collected dialysate before the 
protein is cleared. Additionally, it is important to remember that microdialysis sampling provides 
a time-averaged sample.
16
 Depending on the time average, it is possible that concentrations could 
be similar between both dialysis probes. Then, after the initial injury, the dialysis probe may 
serve as a sink to help clear out some of the initially released cytokines. At this point, cytokines 
may be coming from local cells surrounding the dialysis probe resulting in much lower 
concentrations collected into the dialysate.      
Once the initial cells have started to respond to the injury by producing their own 
cytokines increases in concentration are observed at 90, 120, 150 minutes. We have previously 
observed such increases in cytokines after implantation injury in the subcutaneous tissue.
17
 At 
the 180 minute time point, the CCL2 concentration in the dialysate for the antibody-perfused 
probe was over the high end of the range (2000 pg/mL) and thus cannot be quantified.   
Since this is a reported short communication, there is a significant amount of additional 
validation that would be necessary to more fully elucidate the biological events that are occurring 
after probe insertion. Furthermore, our long-term goal is to perform these studies in awake and 
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freely-moving animals and the concentrations from such studies may be very different than 
observed here.   
In mouse homogenized brain, measured concentrations of CCL2 were reported as 50 
pg/mg protein and 275 pg/mg protein at time points of 90 and 180 minutes respectively after a 
lipopolysaccharide (LPS) injection.
18
 It is our understanding that in rodents, CCL2 has only been 
extracted from brain tissue via the use of homogenized tissues. Although the exact amount of 
brain volume from which this protein amount has been derived is unknown, the homogenized 
tissue CCL2 concentrations are presented as a general reference to compare the concentrations.   
Recently, the collection of CCL2 from human brain has been reported from head trauma 
patients.
19
 From these patients, median CCL2 values found in dialysates were reported to be 
between 2500 – 2550 pg/mL. For comparison, it is important to note that human microdialysis 
catheters have 10 mm long membranes compared to the 4-mm membranes used in our study.  
Additionally, flow rates of 0.3 µL/min were used in the Helmy et al. study vs. 2 µL/min in this 
study.  Smaller membrane lengths and higher perfusion fluid flow rates would lead to lower 
relative recovery values and lower collected CCL2 concentrations reported for this study.  Here 
we report CCL2 concentrations in control dialysates between 260 and 700 pg/mL and antibody 
enhanced values as high as 1735 pg/mL throughout the experimental collection period.   
For IL-6 no significant difference was found between the Antibody enhanced and control 
collection in both the in vitro and in vivo. In both of the in vitro and in vivo an average increase is 
seen in the antibody enhanced and control however variation is too large in the antibody 
enhanced to state that there is a significant difference between the two. In the in vitro data re 
report an average almost two times greater than that of the control. In the in vivo at initial time 
points there appears to be no difference between antibody enhanced and control. At later time 
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points the average in the antibody enhanced starts to increase over the control to be again two 
times that of the control. Again the variation was too large in the antibody enhanced to determine 
a significant difference though. Winter et al report a relative recovery of 45.29±/8.4% for in vitro 
collection of IL-6, in comparison to our 17.6%.
20
 The differences in the probe length, membrane 
molecular weight cut off, and flow rate would explain this difference. The length used by Winter 
et al was 12-15mm in compared to the 4mm length of the probe used in these data, the molecular 
weight cut off was smaller at 3000 kDa in comparison to 10,000 kDa in these data, and the flow 
rate Winter et al. used was 1µL/min in comparison to 2 µL/min that was used for these data, all 
of these would contribute to a larger relative recovery of IL-6 by Winter et al. In vivo Winter et 
al report a max value of 800 pg/mL for IL-6 from human brain tissue.
20
 Godbout et al. report a 
basal concentration of about 100 pg/mL in mouse were we report a concentration of about 250 
pg/mL at similar time points.
21
 There are many possible reasons for these differences between 
our values and those of others including the foreign body or wounding response to the probe, the 
difference in species, and other methodological differences between the different studies.      
The optimization of the use of a detection antibody in the perfusion fluid allowed for 
straight-forward measurement of the samples using a standard ELISA plate and kit.  This initial 
work presented here paves the way for trying the antibody-enhancement approach to many other 
soluble protein targets in the brain ECF.  
One concern when these data were presented was the concern that the extra detection 
antibody in the samples may have had an effect on the assay. To test this theory standard were 
prepared in two solutions. The first was a 1:500 dilution of the detection antibody in aCEF and 
the second was the assay diluent that is kit protocol for the standards.  The results showed that 
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for CCL2 there was no significant difference between the standards prepared with the 1:500 
dilution of antibody to those of just assay diluent.  
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3.6 Appendix  
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 4.0 Development of an In-House Created CCL2 Bead Assay 
 
4.1 Introduction 
 
Detection of multiple cytokines with in the same sample is of a discernible interest for 
comparison studies.  Such comparison studies could give an insight into the greater 
understanding of any possible regulatory roles that cytokines may have on other neurological 
functions as well as wound healing. The ability to multiplex samples would reduce the number of 
samples needed. It could possibly eliminate run to run errors in comparison studies of two 
corresponding intervals when you are looking for neuropeptides. For these experiments a flow 
cytometry system was used that has allowed for the multiplexing of cytokines. The method of 
this flow cytometry was discussed in Chapter 1. In quick summary the Luminex method allows 
the use of different bead types.  These bead types have different antibody attached to them. The 
Luminex instrument is able to differentiate between these bead types, thus allowing for the use of 
several types of beads at the same time.  Each bead type could be a different cytokine being 
analyzed.   
In these experiments it will attempted to mimic the attachment chemistry used in 
commercial beads that have bound cytokine antibodies. Determination and successful mimicry of 
this chemistry will allow us to attach cytokine antibodies to the beads. This will allow us to 
develop multiplexed assays of cytokines that may not have a commercially available kit.  
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4.2 Materials and Methods 
 
4.2.1 Materials 
 
Luminex xMAP carboxylated microspheres (Austin, TX) Bead set 160.  Phycoerythrin 
conjugated F(ab’)2 fragment of affinity purified anti-rabbit IgG from Donkey purchased from 
Rockland (Gilbertsville, PA). Bovine serum albumin, 2[N-morpholino]ethansulfonic acid (MES) 
and sodium azide were purchased from Sigma (St. Louis, MO). Sodium chloride, potassium 
chloride, sodium phosphate monobasic and TWEEN-20 from Fisher Scientific (Pittsburgh, PA). 
Polylink 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) was purchased 
from Polysciences, Inc. (Warrington, PA). Sulfosuccinimidyl-6-[biotin-amido]hexanoate (sulfo-
NHS-LC-biotin), N-hydroxysuccinimide (NHS) and EZ Biotin Quantitation Kit were purchased 
from Pierce (Rockford, IL). Streptavidin, R-phycoerythrin conjugate (SAPE) was purchased 
from Invitrogen (Eugene, OR) Activation buffer -0.1M sodium phosphate monobasic, pH 6.2, 
Coupling buffer - 0.05M 2-(Nmorpholino) ethanesulfonic acid (MES), pH 5.0, PBS-TBN 
blocking/storage buffer for beads - PBS, 0.1% BSA,  0.05% azide, pH 7.4, Assay buffer - PBS, 
1% BSA, pH 7.4, Wash buffer - PBS, 0.05% TWEEN-20, pH 7.4. PBS buffers all contain 138 
mM NaCl and 2.7 mM KCl. Multiscreen HTS, BV 96-well filter plates were purchased from 
Millipore (Billerics, MA). Purified mouse anti-rat MCP-1 (Cat# 555072) and Biotin Mouse anti-
Rat MCP-1(Cat# 555074) were purchased from BD Biosciences Pharmigen. Milliplex Map Rat 
Cytokine/Chemokine Immunoassay (Cat# RCYTO-80k-04) was purchased from Millipore.  
4.2.2 Instruments 
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Luminex
100
 IS (Luminex), ISS-PC1 photon counting spectroflourometer (Vinci). 
4.2.3 Bead Preperation 
 
The stock beads were resuspended by vortex and sonicated. Next, 400 µL of stock beads 
were transferred into a 1.5 mL microcentrifuge tube and pelleted at 10000 x g for 2 minutes. The 
supernatant was removed and the beads were resuspended in 100 µL of HLPC grade water, 
vortexed and pelleted. The supernatant was removed and 80 µL of 100 mM monobasic sodium 
phosphate, pH 6.2 was added and the beads were vortexed. Next 10 µL of 50 mg/mL of NHS 
(diluted in HLPC water) was added and the beads were vortexed. Then, 10 µL of 50 mg/mL 
EDC (diluted in HPLC water) was added and the beads were vortexed. The beads were then 
incubated for 20 minutes with 10 minutes intervals of mixing. The activated beads were 
centrifuged, supernatant removed and 250 µL of 50 mM MES, pH 5.0 was added. The beads 
were vortexed and pelleted and supernatant removed. The beads were washed again using MES 
for a total of 2 washes. Next, the beads were resuspended in 100 µL of 50 mM MES and 
vortexed. Then 10 µL of stock antibody was added and 390 µL of 50 mM MES was added to 
bring the total volume up to 500 µL. The reaction proceeded on a plate shaker at room 
temperature for 2 hours. Next, the beads were pelleted, supernatant removed and the beads were 
vortexed in 1 mL of PBS buffer. The beads were pelleted, supernatant removed and washed 
again with PBS buffer for a total of 2 washes. Finally, the beads were resuspended in 1 mL of 
PBS- buffer and counted using a hemocytometer. 
4.2.4 Protocol for Sandwich Immunoassay 
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The beads were resuspended by vortex and sonication for 20 seconds. A working bead 
mixture was prepared by diluting the coupled beads to a final concentration of 100 beads/µL in 
assay buffer. A 96-well filter plate was pre-wetted and 25 µL of assay buffer was added to each 
well + 25 µL of sample + 25 µL of beads. The plate was covered with foil and allowed to mix on 
a plate shaker overnight at 4ºC. Next, the plate was washed 3X using wash buffer and 50 µL of 
10 µg/mL of detection antibody was added to was well. The plate was incubated at room 
temperature on a shaker for 2 hours. The plate was washed again 3X with wash buffer and 100 
µg/mL of SAPE was added to each well and the plate incubated on the shaker for 1 hour. The 
plate was washed a final time (3X) using wash buffer and then 100 µL of sheath fluid was added 
to each well for analysis. The plate was then analyzed using the Luminex system. 
 
4.3 Results 
 
For the commercially available kit an average of Mean Fluorescence  Intensity(MFI) of 
12734±132, 11375±105, 6198±86, 699±37, 78±8, 10±3, 4±2 are reported for concentrations of 
20,000, 5000, 1250, 312.5, 78.13, 19.53, and 4.88pg/mL of MCP-1 respectively were n=3. For 
the home made assay MFIs of 8328±94, 7982±103, 3712±56, 146±12, 62±9, 10±3, 5±2 are 
reported for concentrations 20,000, 5000, 1250, 312.5, 78.13, 19.53, and 4.88pg/mL of MCP-1 
respectively were n=3.  This data is shown in Figure 4.1.  
The homemade kit shows a significant decrease in MFI at the higher levels of 
concentration of 20,000, 5000, 1250, and 312.5pg/mL. However there is no significant difference 
at the 78.13, 19.53, and 4.88pg/mL concentrations.  
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Figure 4.1 Comparison of  MFIs (n=3) of decreasing concentrations of MCP-1 from 
commercially bought Luminex kit vs Home Made kit.  
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4.4 Discussion 
 
In these experiments it was attempted to create a homemade fluorescence sandwich 
assay. It was believed that variation was caused by the difference in the antibody pairs that were 
used. This different binding affinity could cause the variation in the level of attachment and thus 
MFI.  The commercially used antibodies clones were considered a trade secret and thus true 
comparison with the same antibody clone could not be done. However, results could also be 
evidence of better attachment of the capture antibody in the commercially available assay. 
Comparison of the amount of attachment could not be performed as the detection of the C-
terminus of the capture antibody was attached to the bead. Thus, a detection antibody of the 
capture antibody was unable to be used. Further studies can be done to insure that this 
attachment method works properly for the attachment of similar animal antibodies developed for 
cytokines.  
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5.0 Conclusions 
 
As mentioned in chapter one, cytokines have been linked to neurological diseases 
including, but not limited to Huntington’s, alcoholism, and HIV dementia. Cytokines have also 
been found to have a correlation and possibly causation in several neurological disorders 
including Epilepsy and Cerebral Infarct (Stroke).  It is important to know that many of the 
functions of cytokines are concentration dependent. Changes in the concentration of cytokines 
can reveal stages of wound development or the presence of a disease state. Because of this a 
method of detecting cytokine concentration over times is needed. Microdialysis is a method that 
allows the collection of cytokines from the target area and allows for a time lapse analysis of 
changes in concentration. However microdialysis has limitations in collecting cytokines, the 
work presented in this thesis attempts to overcome some of those limitations and develop 
methods that will allow for a wider use of microdialysis in clinical treatment studies.  
 One of these limitations is that cytokines have a low relative recovery. This presents a 
problem in detection and detection methods. Cytokines are in low concentrations in vivo, about 
the low pico- molar range. Low relative recovery means that even less cytokine is present in the 
sample which may make detection and quantification difficult. In chapter two, experiments to 
develop new methods of cytokine collection using microdialysis are presented. In these 
experiments a method termed Stopped Flow are used to try and improve the relative recovery. In 
Stopped Flow microdialysis the perfusion fluid is stopped for a set time to allow for a longer 
residence time. This increase in residence time it was hypothesized increase the relative 
recovery.  
71 
 
 In these experiments however it was found that while an average increase in the relative 
recovery was gained. A significant difference could not be determined because of the large 
variation. An experiment using methyl orange was then done to see if the variation could be 
reduced. In the methyl orange collection a significant difference was seen in the stopped flow 
from the continuous flow at the 95% confidence interval. With these data it is believe that the 
variation in the cytokine stopped flow experiment was due to the molecule size and the tortious 
path that it had to travel to get through the membrane. Valuable information about the diffusion 
of the molecules and the nature and relation of the membrane/cytokine interaction is shown and 
could lead in future research to a greater understanding of this complex process of microdialysis 
collection.   In this study we attempt to improve the collection by manipulating the parameters of 
the flow alone. Further research could focus on different intervals as well as different collection 
flow rates. These experiments could identify a variation that allowed for a greater collection of 
cytokines without the addition of affinity agents.  
 Previous studies have improved the collection by adding affinity agents, such as Heparin 
to the perfusion fluid.
1
 In chapter three a method of collection of cytokines from in vivo brain 
tissue using antibodies as affinity agents is presented. The use of antibodies as affinity agents 
increases the relative recovery by reducing the amount of free agent in the perfusion fluid. By 
binding the analyte as it enters the perfusion fluid equilibrium forces drive more into the 
perfusion fluid. In these studies a greater recovery of cytokines was found using the antibody 
affinity agents. Free antibody used in the perfusion fluid increased the relative recovery of CCL2 
by 3 fold in both in vitro and in vivo. Free antibody in the perfusion fluid showed an increase in 
the average relative recovery of IL-6 however the variation was too large to say that this was a 
significant difference in both in vitro and in vivo. Experiments were done to see if the free 
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antibody in the perfusion fluid caused interference with the ELISA. Data presented here in this 
thesis show that at the 95% confidence interval free antibody in the perfusion fluid does not have 
a significant difference than the assay diluent used by the kits.   
This study however, was limited by the time of the rat survival under anesthesia. In 
further studies the animal would be awake and free to move allowing for a much longer 
collection period that extending into days. In addition, further studies could look into the 
collection of neuropeptides as well as cytokines, using the antibody affinity agent method.  Work 
done on inhibition of the production of cytokines
2
, could also be used as treatment experiments. 
The implication and uses of this method extends beyond the scope this discussion. They cannot 
all be fully discussed here due to numerous options. Refinement of this method may lead to the 
inclusion of the affinity agent method into clinical trials that are already being conducted with 
microdialysis
3
. 
In chapter four a method for the production of bead based assays is presented. These bead 
based assays are of interest for current cytokine research because of the ability to multiplex with 
them. Since the cytokine network has many factors that regulate it is of great interest to be able 
to be able to quantify many of them in the same sample.  There are currently commercially 
available kits for multiplexing several cytokines. However some of the cytokines are not 
available as well as some of the smaller molecules that are of interest in wound healing and 
neurological disease states. In chapter four a method is developed to create beads that have 
antibodies for these cytokines that do not have current commercially available kit or these 
smaller molecules that do not have a sandwich assay available. These data presented in chapter 
four shows that using this attachment chemistry can be used to make beads that are similar to 
commercially available kits. Further development of this attachment and use of beads could lead 
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to the production of a competitive assay for molecules that are too small for the possibility of 
sandwich assays.
4
  
 In final conclusion the experiments presented here address some of the major concerns 
with microdialysis sampling of cytokines.  The research presented provides insight and methods 
to improve future work done in the collection of cytokines with microdialysis. This work can 
eventually lead to the clinical use of microdialysis as a means of marker identification of disease 
states, wound healing response control, neuro-communication understanding, and many other 
fields that go beyond our current understanding and use of microdialysis. 
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